CNTA Stock Overview
A clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Centessa Pharmaceuticals plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$10.18 |
52 Week High | US$12.45 |
52 Week Low | US$4.91 |
Beta | 1.4 |
1 Month Change | 15.81% |
3 Month Change | -5.30% |
1 Year Change | 79.23% |
3 Year Change | -59.13% |
5 Year Change | n/a |
Change since IPO | -53.20% |
Recent News & Updates
Recent updates
Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point
Apr 24Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?
Mar 07Centessa Pharmaceuticals snaps multi-day losing streak; up 10%
Oct 20Centessa hemophilia B therapy SerpinPC gets FDA orphan drug status
Sep 14Centessa Pharmaceuticals GAAP EPS of -$0.69
Aug 10Checking In On Centessa Pharmaceuticals
Dec 23Centessa Pharmaceuticals stock pops 20%+ intraday to post-IPO high
Jun 14Shareholder Returns
CNTA | US Biotechs | US Market | |
---|---|---|---|
7D | 15.7% | 0.02% | 1.2% |
1Y | 79.2% | 6.7% | 20.6% |
Return vs Industry: CNTA exceeded the US Biotechs industry which returned 7.4% over the past year.
Return vs Market: CNTA exceeded the US Market which returned 20.5% over the past year.
Price Volatility
CNTA volatility | |
---|---|
CNTA Average Weekly Movement | 7.5% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.5% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CNTA has not had significant price volatility in the past 3 months.
Volatility Over Time: CNTA's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2020 | 77 | Saurabh Saha | www.centessa.com |
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy.
Centessa Pharmaceuticals plc Fundamentals Summary
CNTA fundamental statistics | |
---|---|
Market cap | US$1.12b |
Earnings (TTM) | -US$138.42m |
Revenue (TTM) | US$6.85m |
167.9x
P/S Ratio-8.3x
P/E RatioIs CNTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CNTA income statement (TTM) | |
---|---|
Revenue | US$6.85m |
Cost of Revenue | US$0 |
Gross Profit | US$6.85m |
Other Expenses | US$145.27m |
Earnings | -US$138.42m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.22 |
Gross Margin | 100.00% |
Net Profit Margin | -2,019.80% |
Debt/Equity Ratio | 35.7% |
How did CNTA perform over the long term?
See historical performance and comparison